These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14639615)

  • 1. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.
    Kilkkinen A; Virtamo J; Vartiainen E; Sankila R; Virtanen MJ; Adlercreutz H; Pietinen P
    Int J Cancer; 2004 Jan; 108(2):277-80. PubMed ID: 14639615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
    Kilkkinen A; Virtamo J; Virtanen MJ; Adlercreutz H; Albanes D; Pietinen P
    Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1209-12. PubMed ID: 14652283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
    Pietinen P; Stumpf K; Männistö S; Kataja V; Uusitupa M; Adlercreutz H
    Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.
    Stattin P; Adlercreutz H; Tenkanen L; Jellum E; Lumme S; Hallmans G; Harvei S; Teppo L; Stumpf K; Luostarinen T; Lehtinen M; Dillner J; Hakama M
    Int J Cancer; 2002 May; 99(1):124-9. PubMed ID: 11948503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study.
    Vanharanta M; Voutilainen S; Lakka TA; van der Lee M; Adlercreutz H; Salonen JT
    Lancet; 1999 Dec 18-25; 354(9196):2112-5. PubMed ID: 10609816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
    Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
    Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating enterolactone and risk of breast cancer: a prospective study in New York.
    Zeleniuch-Jacquotte A; Adlercreutz H; Shore RE; Koenig KL; Kato I; Arslan AA; Toniolo P
    Br J Cancer; 2004 Jul; 91(1):99-105. PubMed ID: 15226762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
    Piller R; Chang-Claude J; Linseisen J
    Eur J Cancer Prev; 2006 Jun; 15(3):225-32. PubMed ID: 16679865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma enterolactone and breast cancer incidence by estrogen receptor status.
    Olsen A; Knudsen KE; Thomsen BL; Loft S; Stripp C; Overvad K; Møller S; Tjønneland A
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2084-9. PubMed ID: 15598765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of serum enterolactone concentration.
    Kilkkinen A; Stumpf K; Pietinen P; Valsta LM; Tapanainen H; Adlercreutz H
    Am J Clin Nutr; 2001 Jun; 73(6):1094-100. PubMed ID: 11382665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum enterolactone concentration and the risk of coronary heart disease in a case-cohort study of Finnish male smokers.
    Kilkkinen A; Erlund I; Virtanen MJ; Alfthan G; Ariniemi K; Virtamo J
    Am J Epidemiol; 2006 Apr; 163(8):687-93. PubMed ID: 16510545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.
    Guglielmini P; Rubagotti A; Boccardo F
    Breast Cancer Res Treat; 2012 Apr; 132(2):661-8. PubMed ID: 22094938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma enterolactone and breast cancer risk in the Nurses' Health Study II.
    Xie J; Tworoger SS; Franke AA; Terry KL; Rice MS; Rosner BA; Willett WC; Hankinson SE; Eliassen AH
    Breast Cancer Res Treat; 2013 Jun; 139(3):801-9. PubMed ID: 23760859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating enterolactone and risk of endometrial cancer.
    Zeleniuch-Jacquotte A; Lundin E; Micheli A; Koenig KL; Lenner P; Muti P; Shore RE; Johansson I; Krogh V; Lukanova A; Stattin P; Afanasyeva Y; Rinaldi S; Arslan AA; Kaaks R; Berrino F; Hallmans G; Toniolo P; Adlercreutz H
    Int J Cancer; 2006 Nov; 119(10):2376-81. PubMed ID: 16929490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An incident case-referent study on plasma enterolactone and breast cancer risk.
    Hultén K; Winkvist A; Lenner P; Johansson R; Adlercreutz H; Hallmans G
    Eur J Nutr; 2002 Aug; 41(4):168-76. PubMed ID: 12242585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum enterolactone and prognosis of postmenopausal breast cancer.
    Buck K; Vrieling A; Zaineddin AK; Becker S; Hüsing A; Kaaks R; Linseisen J; Flesch-Janys D; Chang-Claude J
    J Clin Oncol; 2011 Oct; 29(28):3730-8. PubMed ID: 21900115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of plasma enterolactone and prostate cancer risk (Sweden).
    Stattin P; Bylund A; Biessy C; Kaaks R; Hallmans G; Adlercreutz H
    Cancer Causes Control; 2004 Dec; 15(10):1095-102. PubMed ID: 15801493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.
    Sonestedt E; Borgquist S; Ericson U; Gullberg B; Olsson H; Adlercreutz H; Landberg G; Wirfält E
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3241-51. PubMed ID: 18990767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of oral antimicrobials decreases serum enterolactone concentration.
    Kilkkinen A; Pietinen P; Klaukka T; Virtamo J; Korhonen P; Adlercreutz H
    Am J Epidemiol; 2002 Mar; 155(5):472-7. PubMed ID: 11867359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis.
    Seibold P; Vrieling A; Johnson TS; Buck K; Behrens S; Kaaks R; Linseisen J; Obi N; Heinz J; Flesch-Janys D; Chang-Claude J
    Int J Cancer; 2014 Aug; 135(4):923-33. PubMed ID: 24436155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.